Abstract 1257P
Background
Double heterozygous (DH) is a rare event, in DH patients, two pathogenic variants (PV) in two genes are present in the genomic DNA. Next-generation sequencing technologies with expanded gene, and affordable and more complete tools for diagnosis in hereditary cancer field, resulted in the identification of unexpected variants, including more than one variant in a single patient. The aim of this study was to identify the prevalence of double heterozygous and determine the effect of two pathogenic variants in hereditary cancer syndromes patients from Northeast Mexico.
Methods
This multicentric study included patients from the CECIL (The CUCC Early Cancer Detection Clinic) Hereditary Cancer Registry, and from the Hereditary Cancer Program from Tec Salud. Both centers accomplish patients of the Nuevo León state and adjacent states of Northern Mexico. Patients were recruited in a period of 7 years (from March of 2016 to March of 2023), a total of 872 patients were evaluated by Medical Geneticists and tested with NGS multigene cancer panel tests.
Results
A total of 294 (33.7%) patients had at least one PV, and 9 (3%) DH (two PV). Of all the DH patients, 8 (88.8%) had the clinical diagnosis of HBOC (Hereditary Breast Hereditary Cancer Syndrome), and one (11.1%) had Lynch Syndrome diagnosis. The mean age of cancer diagnosis was 42.8 years, compared with 40.3 mean for all the analyzed patients. None of the DH patients (0%) had synchronic or metachronic neoplasias diagnosed, compared to 19 (6.46%) with one PV patients. Among the identified variants BRCA1/2 and other homologous repair genes were found in 8 (88.8%) patients. The most frequent gene identified was MUTYH in 5 (55.5%) patients, surprisingly the variant c.1187G>A, known as a founder mutation in Northern Europe, was found in 4/5 (80%). These four Mexican patients had not known European ancestry.
Conclusions
This study suggest that the concurrence of two pathogenic variants did not impact the age of diagnosis or the risk of developing multiple neoplasia. variant c.1187G>A MUTYH founder mutation is frequent in our mestizo population and the most frequently found in the double heterozygous state.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centro Universitario Contra el Cancer Hospital Dr Jose Eleuterio Gonzalez UANL. Centro de Cancer de Mama Hospital Zambrano Hellion Tec Salud.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1794P - Prognostic role of metastatic site in patients with de novo metastatic prostate cancer: A population-based analysis in new hormonal agents era
Presenter: Emre Yekeduz
Session: Poster session 14
1795P - China ARCHES: A multicenter phase III randomized double-blind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) + androgen deprivation therapy (ADT) vs PBO + ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Gongqian Zeng
Session: Poster session 14
1796P - Real-world analysis of metastatic hormone-sensitive prostate cancer: Are randomized clinical trials more trustworthy? Insights from PIONEER, the European network of excellence for big data in prostate cancer
Presenter: Juan Gómez Rivas
Session: Poster session 14
1797P - Application of novel machine learning model in [68Ga] Ga-PSMA-11 PET/CT: Predicting survival in oligometastatic prostate cancer patients
Presenter: Mikaela Dell'Oro
Session: Poster session 14
1800P - Differential tumor gene-expression profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (dn-mCSPC) versus (vs.) mCSPC relapsing after prior localized therapy (PLT-mCSPC)
Presenter: Vinay Mathew Thomas
Session: Poster session 14
1803P - Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with <italic>AR</italic> ligand-binding domain (LBD) mutations
Presenter: Daniel Petrylak
Session: Poster session 14